Pubblicazioni

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer. A single-institution experience

2015 - CANCER CHEMOTHERAPY AND PHARMACOLOGY
Petrioli, R; Francini, E; Roviello, F; Marrelli, D; Fiaschi, Ai; Laera, L; Rossi, G; Bianco, V; Brozzetti, Stefania; Roviello, G.

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

2015 - CANCER CHEMOTHERAPY AND PHARMACOLOGY
De Iuliis, Francesca; Salerno, Gerardo; Taglieri, Ludovica; Scarpa, Susanna

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma